Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions
The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …
Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer
Purpose: Invasive lobular carcinoma (ILC) represents the second most common histologic
breast cancer subtype after invasive ductal carcinoma (IDC). While primary ILC has been …
breast cancer subtype after invasive ductal carcinoma (IDC). While primary ILC has been …
[HTML][HTML] Liquid biopsy in breast cancer
M Banys-Paluchowski, N Krawczyk… - Geburtshilfe und …, 2020 - thieme-connect.com
In den letzten Jahren gewinnt die Liquid Biopsy, dh die blutbasierte Untersuchung von
zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom …
zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom …
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Abstract Background Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in
oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated …
oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated …
Tumor tissue-versus plasma-based genotyping for selection of matched therapy and impact on clinical outcomes in patients with metastatic breast cancer
N Vidula, A Niemierko, G Malvarosa, M Yuen… - Clinical Cancer …, 2021 - AACR
Purpose: Actionable mutations can guide genotype-directed matched therapy. We evaluated
the utility of tissue-based and plasma-based genotyping for the identification of actionable …
the utility of tissue-based and plasma-based genotyping for the identification of actionable …
Update Breast Cancer 2020 Part 2–Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
D Lüftner, A Schneeweiss, AD Hartkopf… - Geburtshilfe und …, 2020 - thieme-connect.com
Für Patientinnen mit einem lokal fortgeschrittenen bzw. metastasierten Mammakarzinom
wurden in den letzten Jahren neue und effektive Therapien wie CDK4/6-Inhibitoren, PARP …
wurden in den letzten Jahren neue und effektive Therapien wie CDK4/6-Inhibitoren, PARP …
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer
AN Shah, KJ Carroll, L Gerratana, C Lin… - Breast Cancer Research …, 2021 - Springer
Background Clinical and genomic data from patients with early-stage breast cancer suggest
more aggressive disease in premenopausal women. However, the association between …
more aggressive disease in premenopausal women. However, the association between …
Stratégies pour la prise en charge des cancers du sein métastatiques récepteurs hormonaux positifs hormonorésistants
T Grellety, N Hajjaji, T Petit, C Bailleux - Bulletin du Cancer, 2023 - Elsevier
Résumé Les cancers du sein RH+ sont définis par la proéminence des voies de
signalisations sous dépendance du récepteur aux œstrogènes. L'hormonothérapie est le …
signalisations sous dépendance du récepteur aux œstrogènes. L'hormonothérapie est le …
[HTML][HTML] Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast …
N Vidula, LW Ellisen, A Bardia - Oncotarget, 2021 - ncbi.nlm.nih.gov
Plasma based genotyping via cell-free DNA may identify actionable mutations for potential
therapeutic intervention in patients with advanced malignancies including breast cancer. In …
therapeutic intervention in patients with advanced malignancies including breast cancer. In …